

Peer Review

Review of: "Scalable Antigen-Antibody Binding Affinity Landscape: A Case Study with ENHERTU"

Moolchand Sharma¹

1. Guru Gobind Singh Indraprastha University, India

1. The abstract is overly dense and repeats several terms. Consider removing phrases like “high-accuracy” and “technically feasible” unless supported by comparative validation.
2. Clarify that “ENHERTU” contains trastuzumab, not both trastuzumab and pertuzumab, to prevent misinterpretation.
3. Expand briefly on why too high a K_d hinders tissue penetration—e.g., due to the “binding-site barrier” effect.
4. Introduce and define “Modigy” more clearly earlier—it’s a coined term combining Modeller and Prodigy but is not self-explanatory.
5. Improve the resolution and labeling of figures.
6. Include legends and axis units (e.g., clearly label K_d values on histograms).
7. Address explicitly that while pertuzumab is not part of ENHERTU, it is included here for synergistic modeling. This distinction is important for clarity.
8. Some references are repeated or inconsistently formatted (e.g., with extra symbols like “a, b, c”). Ensure uniform formatting per journal or preprint guidelines.

Declarations

Potential competing interests: No potential competing interests to declare.